Is Pfizer eyeing the CAR-T bandwagon? Rumours of €1.5bn takeover talks with Cellectis
CRISPR patent claimant Cellectis has declined to comment on rumours US drug giant Pfizer is in talks about a €1.5bn takeover.
Archives for May 28, 2015
Crescendo awarded grant to validate antibody fragment-drug conjugates
Innovate UK has awarded Crescendo Biologics a grant to fund development of drugs combining cytotoxic small molecule payloads with antibody fragments known as Humabodies.